Post-conization surveillance in an organized cervical screening program with more than 23,000 years of follow-up

Avalon Sundqvist; Johanna Nicklasson; Pernilla Olausson; Christer Borgfeldt

doi:10.1186/s13027-023-00545-4

Post-conization surveillance in an organized cervical screening program with more than 23,000 years of follow-up

Infect Agent Cancer. 2023 Dec 6;18(1):81. doi: 10.1186/s13027-023-00545-4.

Authors

Avalon Sundqvist¹, Johanna Nicklasson², Pernilla Olausson³, Christer Borgfeldt²

Affiliations

¹ Department of Obstetrics and Gynecology, Skåne University Hospital, Lund University, Lund, Sweden. avalon.sundqvist@med.lu.se.
² Department of Obstetrics and Gynecology, Skåne University Hospital, Lund University, Lund, Sweden.
³ Data Analysis and Register Centre, Region Skåne, Lund, Sweden.

Abstract

Background: Cervical cancer is preventable through screening and vaccination against high-risk human papillomavirus (hr-HPV). For a screening program to be successful it is vital that the clinical management and follow-up regime of patients with abnormal screening results is well developed and that the attendance rate for follow-up is high. The aim of the study was to analyze how effective conization with recommended follow-up was in preventing subsequent cervical cancer, and to evaluate how clinical follow-up recommendations are obeyed in the region of Skåne, Sweden.

Methods: All women (n = 8835) who had undergone conization in the region of Skåne, Sweden, between the years of 2015 and 2021 were identified. Individuals with confirmed cervical cancer in the conization material were referred for additional treatment (n = 114), leaving 8721 included in the follow-up. Adherence to follow-up and cytological, histopathological and HPV status at follow-up were collected at eight, 12 and 24 months post-conization. The total follow-up time was from January 1, 2015, to January 30, 2023.

Results: Within 12 months post-conization, 90% of the patients conducted a cytological cervical sample. The rates of a negative test of cure (HPV negative and normal cytology) were 69.7%, 76.3% and 84.4% at eight, 12 and 24 months post-conization respectively. The clearance of HPV was 79.6%, 80.8% and 87.8% at eight, 12 and 24 months post-conization respectively. Out of 5613 patients with a negative test of cure within one year after conization, no cervical cancer was found during follow-up and 11 (0.2%) women developed high-grade intraepithelial lesions/adenocarcinoma in situ (HSIL/AIS) with an average time from conization to new diagnosis of 42 months. The mean follow-up time was 32.1 months.

Conclusions: The clearance rate of hr-HPV post cervical conization due to dysplasia appears to be high within eight months. With a negative test of cure post cervical conization, the risk of cervical cancer within the following three years seems to be extremely low and the risk of developing HSIL/AIS was lower than the incidence of HSIL/AIS in the general screening population.

Keywords: Conization; Human papillomavirus; Posttreatment surveillance; Uterine cervical dysplasia; Uterine cervical neoplasms.